Compare Pfizer with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ASTRAZENECA PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ASTRAZENECA PHARMA PFIZER/
ASTRAZENECA PHARMA
 
P/E (TTM) x 36.5 93.4 39.0% View Chart
P/BV x 6.2 26.3 23.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 PFIZER   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-19
ASTRAZENECA PHARMA
Mar-18
PFIZER/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,8401,278 300.5%   
Low Rs2,080883 235.7%   
Sales per share (Unadj.) Rs455.0228.4 199.2%  
Earnings per share (Unadj.) Rs93.810.4 904.9%  
Cash flow per share (Unadj.) Rs109.416.3 672.7%  
Dividends per share (Unadj.) Rs22.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs658.298.8 666.4%  
Shares outstanding (eoy) m45.7525.00 183.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.54.7 137.5%   
Avg P/E ratio x31.6104.2 30.3%  
P/CF ratio (eoy) x27.166.4 40.7%  
Price / Book Value ratio x4.510.9 41.1%  
Dividend payout %24.00-   
Avg Mkt Cap Rs m135,42027,008 501.4%   
No. of employees `0002.61.4 194.0%   
Total wages/salary Rs m3,2381,535 210.9%   
Avg. sales/employee Rs Th7,911.44,210.9 187.9%   
Avg. wages/employee Rs Th1,230.91,132.2 108.7%   
Avg. net profit/employee Rs Th1,630.7191.1 853.5%   
INCOME DATA
Net Sales Rs m20,8155,710 364.5%  
Other income Rs m1,674123 1,366.4%   
Total revenues Rs m22,4895,833 385.6%   
Gross profit Rs m5,712463 1,234.0%  
Depreciation Rs m714147 484.3%   
Interest Rs m730-   
Profit before tax Rs m6,599438 1,506.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,309179 1,290.4%   
Profit after tax Rs m4,291259 1,655.9%  
Gross profit margin %27.48.1 338.5%  
Effective tax rate %35.040.8 85.7%   
Net profit margin %20.64.5 454.3%  
BALANCE SHEET DATA
Current assets Rs m27,1673,209 846.5%   
Current liabilities Rs m8,9172,070 430.9%   
Net working cap to sales %87.720.0 439.3%  
Current ratio x3.01.6 196.5%  
Inventory Days Days6872 93.7%  
Debtors Days Days3035 86.2%  
Net fixed assets Rs m8,862790 1,121.3%   
Share capital Rs m45850 915.0%   
"Free" reserves Rs m29,6562,419 1,225.8%   
Net worth Rs m30,1132,469 1,219.5%   
Long term debt Rs m250-   
Total assets Rs m39,4004,605 855.5%  
Interest coverage x91.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.2 42.6%   
Return on assets %11.15.6 196.8%  
Return on equity %14.210.5 135.8%  
Return on capital %22.117.7 124.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m428300 143.0%   
Fx outflow Rs m7862,015 39.0%   
Net fx Rs m-358-1,715 20.9%   
CASH FLOW
From Operations Rs m97888 1,112.7%  
From Investments Rs m351-94 -375.2%  
From Financial Activity Rs m-1,099NA-  
Net Cashflow Rs m231-6 -4,049.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 0.3 2,500.0%  
FIIs % 4.9 15.7 31.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 9.1 260.4%  
Shareholders   85,207 12,856 662.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ORCHID PHARMA LTD  CIPLA  JUBILANT LIFE SCIENCES  VENUS REMEDIES  STERLING BIOTECH  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 19, 2019 (Close)

TRACK PFIZER

PFIZER - ALKEM LABORATORIES COMPARISON

COMPARE PFIZER WITH

MARKET STATS